Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Garcia-Manero, Guillermo

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. [electronic resource] - Investigational new drugs Aug 2015 - 870-80 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

1573-0646

10.1007/s10637-015-0242-6 doi


Aged
Aminopyridines--adverse effects
Antineoplastic Agents--adverse effects
Antineoplastic Combined Chemotherapy Protocols
Aurora Kinases--antagonists & inhibitors
Azacitidine--adverse effects
Female
Hematologic Neoplasms--drug therapy
Humans
Male
Maximum Tolerated Dose
Phenylurea Compounds--adverse effects
Protein Kinase Inhibitors--adverse effects
Receptors, Vascular Endothelial Growth Factor